U.S. Markets close in 4 hrs 26 mins
  • S&P 500

    3,771.36
    -11.92 (-0.32%)
     
  • Dow 30

    30,154.75
    -119.12 (-0.39%)
     
  • Nasdaq

    11,139.91
    -8.73 (-0.08%)
     
  • Russell 2000

    1,757.19
    -5.50 (-0.31%)
     
  • Crude Oil

    88.58
    +0.82 (+0.93%)
     
  • Gold

    1,721.40
    +0.60 (+0.03%)
     
  • Silver

    20.60
    +0.06 (+0.30%)
     
  • EUR/USD

    0.9834
    -0.0152 (-1.5242%)
     
  • 10-Yr Bond

    3.8140
    +0.0550 (+1.46%)
     
  • Vix

    29.28
    +0.73 (+2.56%)
     
  • GBP/USD

    1.1187
    -0.0288 (-2.5103%)
     
  • USD/JPY

    144.7950
    +0.5960 (+0.4133%)
     
  • BTC-USD

    20,100.09
    +164.13 (+0.82%)
     
  • CMC Crypto 200

    457.54
    -5.58 (-1.21%)
     
  • FTSE 100

    7,006.52
    -46.10 (-0.65%)
     
  • Nikkei 225

    27,311.30
    +190.77 (+0.70%)
     

Those who invested in Cross Country Healthcare (NASDAQ:CCRN) three years ago are up 150%

·3 min read

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But if you buy shares in a really great company, you can more than double your money. For instance the Cross Country Healthcare, Inc. (NASDAQ:CCRN) share price is 150% higher than it was three years ago. How nice for those who held the stock! Also pleasing for shareholders was the 49% gain in the last three months. The company reported its financial results recently; you can catch up on the latest numbers by reading our company report.

Now it's worth having a look at the company's fundamentals too, because that will help us determine if the long term shareholder return has matched the performance of the underlying business.

View our latest analysis for Cross Country Healthcare

In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.

During three years of share price growth, Cross Country Healthcare moved from a loss to profitability. That kind of transition can be an inflection point that justifies a strong share price gain, just as we have seen here.

You can see how EPS has changed over time in the image below (click on the chart to see the exact values).

earnings-per-share-growth
earnings-per-share-growth

It's good to see that there was some significant insider buying in the last three months. That's a positive. That said, we think earnings and revenue growth trends are even more important factors to consider. Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here..

A Different Perspective

It's good to see that Cross Country Healthcare has rewarded shareholders with a total shareholder return of 25% in the last twelve months. That gain is better than the annual TSR over five years, which is 15%. Therefore it seems like sentiment around the company has been positive lately. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Even so, be aware that Cross Country Healthcare is showing 3 warning signs in our investment analysis , you should know about...

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here